Background. Fludarabine monophosphate (FLU) is an adenine nucleoside analogue with promising therapeutic activity in lymphoproliferative disorders. In addition, the effectiveness of α-interferon (α-IFN) in low-grade non-Hodgkin's lymphoma (LG-NHL) and B-cell chronic lymphocytic leukemia (B-CLL) has been demonstrated in several clinical trials. Methods. In a phase II study of 45 patients with B-CLL and 28 with LG-NHL, we used FLU as second and third-line chemotherapy. Dosages of 25 mg/m2 were given in 30-minute infusions for 5 consecutive days. Treatment was repeated every 28 days depending on patients' clinical status for a maximum of 6 cycles. Entrance in the human lymphoblastoid α-IFN maintenance portion of the study depended on response to initial FLU. Following randomization we administered α-IFN, or no therapy at all, to patients who obtained a complete or a partial response after FLU therapy. The α-IFN dose was 3 x 106 U three times per week until disease progression. Results. Twenty-one B-CLL patients achieved major responses, as did 17 of those with LG-NHL. Twenty-four of the former group and 11 of the latter failed to respond or obtained only a minor response. The 38 patients who responded well and entered the second part of the trial showed significant prolongation of remission duration with maintenance α-IFN. Conclusions. In consideration of its significant activity, the role of FLU in the management of lymphoproliferative disorders needs to be evaluated further; at the same time, this preliminary analysis seems to indicate that maintenance α-IFN may extend remission duration in B-CLL and LG-NHL.

Zinzani, P.L., Levrero, M.G., Lauria, F., Rondelli, D., Zaja, F., Russo, D., et al. (1994). Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. HAEMATOLOGICA, 79(1), 55-60.

Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma

Lauria, F;Gozzetti, A;
1994-01-01

Abstract

Background. Fludarabine monophosphate (FLU) is an adenine nucleoside analogue with promising therapeutic activity in lymphoproliferative disorders. In addition, the effectiveness of α-interferon (α-IFN) in low-grade non-Hodgkin's lymphoma (LG-NHL) and B-cell chronic lymphocytic leukemia (B-CLL) has been demonstrated in several clinical trials. Methods. In a phase II study of 45 patients with B-CLL and 28 with LG-NHL, we used FLU as second and third-line chemotherapy. Dosages of 25 mg/m2 were given in 30-minute infusions for 5 consecutive days. Treatment was repeated every 28 days depending on patients' clinical status for a maximum of 6 cycles. Entrance in the human lymphoblastoid α-IFN maintenance portion of the study depended on response to initial FLU. Following randomization we administered α-IFN, or no therapy at all, to patients who obtained a complete or a partial response after FLU therapy. The α-IFN dose was 3 x 106 U three times per week until disease progression. Results. Twenty-one B-CLL patients achieved major responses, as did 17 of those with LG-NHL. Twenty-four of the former group and 11 of the latter failed to respond or obtained only a minor response. The 38 patients who responded well and entered the second part of the trial showed significant prolongation of remission duration with maintenance α-IFN. Conclusions. In consideration of its significant activity, the role of FLU in the management of lymphoproliferative disorders needs to be evaluated further; at the same time, this preliminary analysis seems to indicate that maintenance α-IFN may extend remission duration in B-CLL and LG-NHL.
1994
Zinzani, P.L., Levrero, M.G., Lauria, F., Rondelli, D., Zaja, F., Russo, D., et al. (1994). Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. HAEMATOLOGICA, 79(1), 55-60.
File in questo prodotto:
File Dimensione Formato  
Alpha-interferon as maintenance drug.pdf

accesso aperto

Tipologia: PDF editoriale
Licenza: PUBBLICO - Pubblico con Copyright
Dimensione 137.12 kB
Formato Adobe PDF
137.12 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1063461